Literature DB >> 2927661

Distribution of a putative endogenous modulator of the GABAergic system in human brain.

C Ferrarese1, I Appollonio, M Frigo, R Piolti, F Tamma, L Frattola.   

Abstract

Diazepam binding inhibitor (DBI) is a novel neuropeptide purified from rat, cow, and human brain that allosterically modulates GABAergic transmission by binding to benzodiazepine (BDZ)-recognition sites. Using a specific radioimmunoassay for human DBI, we investigated the distribution of this peptide in different brain areas. We characterized with high-pressure liquid chromatography the DBI immunoreactivity in brain tissue obtained by biopsy and autopsy; we detected one molecular species of DBI in both instances. The regional distribution of DBI in the human brain is similar to that observed in rat brain: high concentrations in cortical and limbic areas, cerebellum, and brainstem, and low concentrations in the basal ganglia. These data suggest a modulatory role for DBI in human brain.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2927661     DOI： 10.1212/wnl.39.3.443

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  Acyl-CoA binding proteins: multiplicity and function.

Authors:  R E Gossett; A A Frolov; J B Roths; W D Behnke; A B Kier; F Schroeder
Journal:  Lipids       Date:  1996-09       Impact factor: 1.880

2.  Subregion-Specific Impacts of Genetic Loss of Diazepam Binding Inhibitor on Synaptic Inhibition in the Murine Hippocampus.

Authors:  Connor D Courtney; Catherine A Christian
Journal:  Neuroscience       Date:  2018-07-19       Impact factor: 3.590

Review 3.  The function of acyl-CoA-binding protein (ACBP)/diazepam binding inhibitor (DBI).

Authors:  J Knudsen; S Mandrup; J T Rasmussen; P H Andreasen; F Poulsen; K Kristiansen
Journal:  Mol Cell Biochem       Date:  1993 Jun 9-23       Impact factor: 3.396

4.  Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy.

Authors:  R Avallone; M L Zeneroli; I Venturini; L Corsi; P Schreier; M Kleinschnitz; C Ferrarese; F Farina; C Baraldi; N Pecora; M Frigo; M Baraldi
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

5.  Modifications of diazepam binding inhibitor and peripheral benzodiazepine receptors in the lymphocytes of epileptic patients.

Authors:  C Ferrarese; M Perego; C Marzorati; G Bianchi; M Frigo; N Pecora; R Riva; G Moretti; L Frattola
Journal:  Ital J Neurol Sci       Date:  1996-04

6.  CSF levels of diazepam-binding inhibitor correlate with REM latency in schizophrenia, a pilot study.

Authors:  D P van Kammen; A Guidotti; T Neylan; P Guarneri; M E Kelley; J Gurklis; M W Gilbertson; J L Peters; E Costa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.